No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Chart series for revenue are being prepared.
No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Chart series for revenue are being prepared.
The latest delayed quote for ADARx Pharmaceuticals, Inc. (ADRX) stock was $19.05 as of Oct 5, 2026, 4:00 PM EDT, up 4.38% from the previous close.
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company.
Specialty Business Services · San Diego, CA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
N/A
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ADRX | $1.95B | $19.05 | +4.38% | N/A | N/A | N/A | N/A |
| 2ALNT | $2.02B | $118.63 | +0.28% | +170.57% | +30.06% | +20.17% | vs ADRX |
| 3ALGT | $2.02B | $75.14 | -3.18% | +19.57% | -17.33% | -5.06% | vs ADRX |
| 4ARXS | $2.03B | $50.13 | +0.20% | N/A | N/A | N/A | vs ADRX |
| 5PLPC | $2.03B | $416.10 | -0.80% | +108.14% | +45.71% | +26.50% | vs ADRX |
| 6EPAC | $1.86B | $36.02 | +1.07% | -12.64% | +10.86% | +4.58% | vs ADRX |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$19.05
High
N/A